Tus%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd

**Tus%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd (Tussionex Pennkinetic)** ## Overview Tussionex Pennkinetic is an extended-release liquid formulation of hydrocodone bitartrate and chlorpheniramine maleate. It is a combination product with antitussive and antihistamine properties. ## Primary Indications * Relief of cough associated with minor throat and bronchial irritation. ## Adult Dosing * **Oral:** 5 mL to 10 mL every 12 hours. Do not exceed 20 mL in 24 hours. ## Pediatric Dosing * Safety and efficacy in pediatric patients below 6 years of age have not been established. * **Oral:** Dosing for children 6 years and older depends on weight and should be determined by a healthcare provider based on local protocol. Typical recommended doses for children 6-12 years are 5 mL every 12 hours. ## Dose Adjustments * **Hepatic Impairment:** Use with caution. Dosing adjustments may be necessary, but specific guidelines are not well-defined. Monitor closely for adverse effects. * **Renal Impairment:** Use with caution. Dosing adjustments may be necessary, but specific guidelines are not well-defined. Monitor closely for adverse effects. ## Contraindications * Hypersensitivity to hydrocodone, chlorpheniramine, or any component of the formulation. * Patients with asthma, lower respiratory tract disease, or severe respiratory depression. * Concurrent use with MAO inhibitors or within 14 days of stopping an MAO inhibitor. * Significant hepatic impairment. ## Adverse Effects **Common:** Sedation, drowsiness, dizziness, constipation, nausea, vomiting, dry mouth, blurred vision, confusion, urinary retention. **Serious:** Respiratory depression, CNS depression, potential for abuse and dependence, hypercapnia, hypotension, allergic reactions. ## Key Drug Interactions * **CNS Depressants (e.g., alcohol, benzodiazepines, opioids, sedatives, hypnotics):** Increased risk of profound sedation, respiratory depression, coma, and death. * **MAO Inhibitors:** Potentiated and unpredictable cardiovascular effects (hypertensive crises) or CNS effects. * **Anticholinergic Agents:** Additive anticholinergic effects (e.g., dry mouth, constipation, urinary retention, blurred vision). * **CYP3A4 Inhibitors (e.g., strong inhibitors like ketoconazole, itraconazole, ritonavir):** May increase hydrocodone plasma concentrations, leading to increased adverse effects. ## Monitoring * Respiratory rate and depth. * Level of consciousness and sedation. * Signs of constipation. * Potential for abuse or dependence. ## Clinical Pearls * Tussionex Pennkinetic contains hydrocodone, a Schedule II controlled substance, and has a potential for abuse and dependence. * Due to the extended-release formulation, it should be swallowed whole and not crushed, chewed, or broken. * The sedative effects can impair a patient's ability to drive or operate machinery. * Concomitant use with other CNS depressants should be avoided or closely monitored. **Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Always consult the most current prescribing information and your healthcare provider for any medical decisions.